T-cell Minimal Residual Disease (MRD) Evaluation Using Flow Cytometric Analysis

This study has been completed.
Sponsor:
Information provided by:
Stanford University
ClinicalTrials.gov Identifier:
NCT01078337
First received: February 26, 2010
Last updated: March 1, 2010
Last verified: February 2010
  Purpose

To determine if MRD (minimal residual disease) can be found in the blood (only) as opposed to bone marrow in children with ALL (acute lymphoblastic leukemia).


Condition Intervention
Leukemia, Lymphocytic, Acute
Procedure: bone marrow aspiration
Procedure: peripheral blood sampling

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: T-cell MRD Evaluation Using Flow Cytometric Analysis

Resource links provided by NLM:


Further study details as provided by Stanford University:

Biospecimen Retention:   Samples With DNA

blood and bone marrow


Estimated Enrollment: 15
Study Start Date: November 2002
Study Completion Date: October 2007
Primary Completion Date: October 2007 (Final data collection date for primary outcome measure)
  Eligibility

Ages Eligible for Study:   up to 18 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

children with newly diagnosed T-cell ALL

Criteria

Inclusion Criteria:

  • Children with newly diagnosed T-cell ALL
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01078337

Locations
United States, California
Stanford University School of Medicine
Stanford, California, United States, 94305
Sponsors and Collaborators
Stanford University
Investigators
Principal Investigator: Gary V Dahl Stanford University
  More Information

No publications provided

Responsible Party: Gary V Dahl, Stanford University School of Medicine
ClinicalTrials.gov Identifier: NCT01078337     History of Changes
Other Study ID Numbers: SU-11022007-790, PEDSALL0001
Study First Received: February 26, 2010
Last Updated: March 1, 2010
Health Authority: United States: Institutional Review Board

Additional relevant MeSH terms:
Leukemia, Lymphoid
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Neoplasm, Residual
Leukemia
Neoplasms by Histologic Type
Neoplasms
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Neoplastic Processes
Pathologic Processes

ClinicalTrials.gov processed this record on October 02, 2014